Jeffrey Trigilio

Jeffrey Trigilio has worked in the financial industry for over 12 years. Jeffrey started their career in 2008 as an Associate at Credit Suisse. In 2013, they joined Alexion Pharmaceuticals, Inc. in various roles, including Executive Director, Senior Director of Strategic Decision Analysis, Director of Long Range Planning, and Corporate Planning and Strategy. In 2017, they moved to RBC Capital Markets as Director of Healthcare Investment Banking. In 2018, they joined BlueRock Therapeutics as Vice President of Corporate Finance. In 2020, they were appointed Chief Financial Officer of both Amylyx Pharmaceuticals and Cullinan Oncology.

Jeffrey Trigilio obtained a Bachelor's Degree in Industrial and Labor Relations from Cornell University between 2002 and 2006. Jeffrey then went on to pursue a Master of Business Administration (MBA) from Columbia Business School, which they completed in 2018.